布比卡因脂质体联合盐酸布比卡因臂丛神经阻滞技术在肱骨近端骨折切开复位内固定术中的应用

注册号:

Registration number:

ChiCTR2500101662 

最近更新日期:

Date of Last Refreshed on:

2025-04-28 10:29:00 

注册时间:

Date of Registration:

2025-04-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

布比卡因脂质体联合盐酸布比卡因臂丛神经阻滞技术在肱骨近端骨折切开复位内固定术中的应用

Public title:

Application of Liposomal Bupivacaine Combined with Bupivacaine Hydrochloride in Brachial Plexus Block for Open Reduction and Internal Fixation of Proximal Humerus Fractures

注册题目简写:

English Acronym:

研究课题的正式科学名称:

布比卡因脂质体联合盐酸布比卡因臂丛神经阻滞技术在肱骨近端骨折切开复位内固定术中的应用

Scientific title:

Application of Liposomal Bupivacaine Combined with Bupivacaine Hydrochloride in Brachial Plexus Block for Open Reduction and Internal Fixation of Proximal Humerus Fractures

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张鹏鹏 

研究负责人:

张鹏鹏 

Applicant:

Pengpeng Zhang 

Study leader:

Pengpeng Zhang 

申请注册联系人电话:

Applicant telephone:

+86 182 5208 5123

研究负责人电话:

Study leader's
telephone:

+86 182 5208 5123

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zppdoc@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

zppdoc@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市浦口区公园北路18号

研究负责人通讯地址:

江苏省南京市浦口区公园北路18号

Applicant address:

No. 18 Gongyuan North Road, Pukou District, Nanjing City, Jiangsu Province

Study leader's address:

No. 18 Gongyuan North Road, Pukou District, Nanjing City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京市浦口区中医院

Applicant's institution:

Nanjing Pukou District Hospital of Traditional Chinese Medicine

研究负责人所在单位:

南京市浦口区中医院

Affiliation of the Leader:

Nanjing Pukou District Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20250002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京市浦口区中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Pukou District Hospital of Traditional Chinese Medicine, Nanjing

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-15 00:00:00

伦理委员会联系人:

豆娟莉

Contact Name of the ethic committee:

Julie Dou

伦理委员会联系地址:

江苏省南京市浦口区公园北路18号

Contact Address of the ethic committee:

No. 18 Gongyuan North Road, Pukou District, Nanjing City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 189 1331 0995

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京市浦口区中医院

Primary sponsor:

Nanjing Pukou District Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省南京市浦口区公园北路18号

Primary sponsor's address:

No. 18 Gongyuan North Road, Pukou District, Nanjing City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京市浦口区中医院

具体地址:

江苏省南京市浦口区公园北路18号

Institution
hospital:

Nanjing Pukou District Hospital of Traditional Chinese Medicine

Address:

No. 18 Gongyuan North Road, Pukou District, Nanjing City, Jiangsu Province

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

肱骨近端骨折  

Target disease:

Proximal Humerus Fracture

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.找到布比卡因脂质体联合盐酸布比卡因用于肌间沟臂丛神经阻滞的最低有效剂量; 2.布比卡因脂质体联合盐酸布比卡因臂丛神经阻滞与单纯布比卡因臂丛神经阻滞在肱骨近端骨折切开复位内固定术后患者镇痛效果及副作用的发生率。  

Objectives of Study:

1. Determine the minimum effective dose of liposomal bupivacaine combined with bupivacaine hydrochloride for interscalene brachial plexus block; 2. Compare the analgesic efficacy and incidence of adverse effects between brachial plexus block with liposomal bupivacaine combined with bupivacaine hydrochloride and brachial plexus block with bupivacaine alone in patients undergoing open reduction and internal fixation (ORIF) of proximal humerus fractures.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.已知有布比卡因脂质体、布比卡因过敏史的患者; 2.术后入ICU监护治疗的患者;术后拒绝进行康复训练的患者; 3.既往长期口服阿片类止痛药的患者,已参与其他药物或临床试验的患者。

Exclusion criteria:

1. Patients with a known history of liposomal bupivacaine and bupivacaine allergy; 2. Patients admitted to ICU for monitoring and treatment after surgery; Patients who refuse to undergo rehabilitation training after surgery; 3. Patients with previous long-term oral opioid analgesics, patients who have participated in other drugs or clinical trials.

研究实施时间:

Study execute time:

From 2025-07-01 00:00:00 To 2026-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-07-07 00:00:00 To 2026-06-26 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

Experimental Group

Sample size:

干预措施:

布比卡因脂质体联合布比卡因

干预措施代码:

Intervention:

Liposomal bupivacaine in combination with bupivacaine

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

布比卡因

干预措施代码:

Intervention:

Bupivacaine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京市浦口区中医院 

单位级别:

三级 

Institution
hospital:

Nanjing Pukou District Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

术后不同时间点静息状态的疼痛评分

指标类型:

主要指标

Outcome:

Postoperative pain scores at different time points in resting state

Type:

Primary indicator

测量时间点:

术后6小时、12小时、24小时 、48小时、72小时

测量方法:

Measure time point of outcome:

6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after surgery

Measure method:

指标中文名:

术后不同时间点进行康复锻炼时的疼痛评分

指标类型:

主要指标

Outcome:

Pain scores during rehabilitation exercises at different postoperative time points

Type:

Primary indicator

测量时间点:

术后6小时、12小时、24小时 、48小时、72小时

测量方法:

Measure time point of outcome:

6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after surgery

Measure method:

指标中文名:

术后静脉镇痛药物使用情况

指标类型:

主要指标

Outcome:

Postoperative intravenous analgesia application

Type:

Primary indicator

测量时间点:

术后当日、第一日、第二日及第三日

测量方法:

Measure time point of outcome:

Postoperative day 0,Postoperative day 1,Postoperative day 2,Postoperative day 3

Measure method:

指标中文名:

术后运动恢复情况

指标类型:

主要指标

Outcome:

Progress of postoperative motor function rehabilitation

Type:

Primary indicator

测量时间点:

术后当日、第一日、第二日及第三日

测量方法:

Measure time point of outcome:

Postoperative day 0,Postoperative day 1,Postoperative day 2,Postoperative day 3

Measure method:

指标中文名:

外周神经阻滞相关不良反应发生率

指标类型:

次要指标

Outcome:

Complication rate of peripheral nerve blocks

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者A使用计算机生成随机序列,分配比例为1:1

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence is generated by researcher A using a computer, with an allocation ratio of 1:1

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对受试者和研究者设盲

Blinding:

Double-blind, blinding the subject and the investigator

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.通过医院电子病历系统进行数据采集; 2.应用Excel和SPSS进行数据处理和保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Collect data through medical records system ; 2. Manage and save data through Excel and SPSS .

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-04-28 10:28:53